“…[6][7][8][9][14][15][16][17][18] A steady growth of interest in Ru(II)-NHC anticancer drugs and photoluminescence study of Ru(II)-NHC complexes over the last 20 years is reflected in the accelerating growth of publications. [13,[19][20][21][22][23] Interestingly, Ru anticancer drugs have been growing rapidly since NAMI-A (ImH+)[RuIIICl4(Im) (S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 (IndH+)-[RuIIICl4(Ind)2], where Ind = indazole, has successfully completed phase-I clinical trials and an array of other Ru complexes have shown promises for future development. [21] Several metals, Cu(I), Ag(I), Au(I), Au(III), Pd(II), Pt(II)-NHC are reported as anticancer drugs.…”